Company / Working Capital
Inhibrx Biosciences, Inc. Working Capital History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$99.0M
FY2025
5-year range
$99.0M / $239.0M
FY2023-FY2025
Trend
-17.2%
vs FY2024
Sector context
#193 of 213
Health Care
What the data says
Among 213 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 9% for working capital. Declined from $239M to $99M over the past 2 years.
Based on SEC 10-K filings.
$99M in FY2025.
Declined from $239M to $99M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 213This company $99.0M Sector average $934.6M
▼
-89.4% below sector average
Key checks
Key Insights
- In FY2025, working capital decreased 17.2% year-over-year.
- Ranks #193 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $99.0M | -17.2% |
| FY2024 | $119.7M | -49.9% |
| FY2023 | $239.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026